
Opinion|Videos|February 28, 2025
Impact of BTK Inhibitors on Treatment Paradigm of CLL and MCL
Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors have transformed the treatment paradigm for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), especially in the frontline setting, by offering effective, targeted therapy that provides significant clinical benefits and improves overall survival compared with traditional chemotherapy.
Advertisement
Episodes in this series

- How have BTK inhibitors transformed the treatment paradigm for patients with CLL and MCL, particularly in the frontline setting?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Amgen Direct-to-Patient Program Aims to Expand Access to Evolocumab Amid US Drug Pricing Reforms
3
Cohere Health Findings on AI in Prior Authorization Conflict With AMA Data
4
Contributor: Why Public Health Keeps Failing—and How to Fix It
5